Secondary Logo

Share this article on:

Is there treatment for Leber hereditary optic neuropathy?

Peragallo, Jason H.a,b; Newman, Nancy J.a,c,d

Current Opinion in Ophthalmology: November 2015 - Volume 26 - Issue 6 - p 450–457
doi: 10.1097/ICU.0000000000000212
NEURO-OPHTHALMOLOGY: Edited by Dean M. Cestari
Editor's Choice

Purpose of review To discuss recent advances in potential treatments for Leber hereditary optic neuropathy (LHON), a typically visually devastating hereditary optic neuropathy caused by mutations in the mitochondrial genome.

Recent findings Idebenone has been proposed as a means of bypassing defective complex I activity and a free radical scavenger to prevent oxidative damage. EPI-743 may have more potency than idebenone, but no clinical trials have been performed. Gene therapy techniques have advanced significantly, including allotopic expression and nuclear transfer. Successful rescue of animal models of LHON with both of these therapies has been demonstrated. Introduction of exogenous DNA into the mitochondrial genome with mitochondrial targeting of viral vectors is another promising technique.

Summary There are currently no proven treatments for LHON. However, there are many promising novel treatment modalities that are currently being evaluated, with several clinical trials underway or in the planning stages. Supportive measures and genetic counseling remain of great importance for these patients.

aDepartment of Ophthalmology

bDepartment of Pediatrics

cDepartment of Neurology

dDepartment of Neurological Surgery, Emory University, Atlanta, Georgia, USA

Correspondence to Nancy J. Newman, MD, Neuro-ophthalmology Unit, 1365-B Clifton Road NE, Atlanta, GA 30322, USA. Tel: +1 404 778 5360; Fax: +1 404 778 4849; e-mail: ophtnjn@emory.edu

Back to Top | Article Outline

INTRODUCTION

Leber hereditary optic neuropathy (LHON) is an inherited bilateral isolated optic neuropathy caused by mutations in the mitochondrial DNA (mtDNA) [1–3] [1–3] [1–3]. Three primary point mutations account for about 90% of LHON cases (m.11778G>A, m.3460G>A, m.14484T>C), with the mutation at the 11 778 locus being the most common and having the worst visual prognosis, and the 14 484 locus associated with the best visual prognosis [1–3] [1–3] [1–3]. These mutations lead to abnormalities in the structure of proteins involved in the mitochondrial respiratory chain within complex I. Altered function of these proteins likely causes some decrease in ATP synthesis, but most importantly an increase in free radical production and oxidative damage.

Classically, LHON presents with bilateral vision loss, which is painless, central, and symmetric [1–3] [1–3] [1–3]. Visual acuities are typically 20/200 or worse bilaterally [1–3] [1–3] [1–3]. The time between involvement of each eye is typically 2–4 months, and second eye involvement occurs in at least 97% of cases within 1 year. Vision loss is usually permanent, although more than 50% of patients who harbor the 14 484 mutation will have some spontaneous improvement. Younger patients have a higher chance of vision recovery, especially those younger than 10 years of age [1,3,4] [1,3,4] [1,3,4]. The optic nerve becomes pale, most significantly temporally, as the papillomacular bundle is preferentially affected.

LHON provides a naturally occurring ‘laboratory’ for novel therapies and clinical trials given the bilateral sequential nature of the disease. In about 50% of cases, this window of opportunity is clinically recognized, allowing for potential prevention of vision loss in the second eye. Also, unique to this piece of central nervous system tissue, therapies can be delivered directly to the tissue involved, in this case to the retinal ganglion cells via intravitreal injection or topical therapy. Treatment effect can be monitored through visual function measures, and objectively measured with retinal ganglion cell layer morphometry using optical coherence tomography. The eye is an immune-privileged site, making it ideal for gene therapy trials with viral vectors. A near 100% rate of involvement of the second eye makes prevention of bilateral occurrence a clearly measurable outcome for treatment trials [5].

Box 1

Box 1

Back to Top | Article Outline

TREATMENTS

General treatments for mitochondrial disease

Various formulations for so-called ‘mitochondrial cocktails’ have been used to treat mitochondrial diseases, including LHON. Coenzyme Q10, L-carnitine, creatine, lipoic acid, dimethylglycine, cysteine, succinate, dichloroacetate, vitamin K1, vitamin K3, vitamin C, vitamin B1, vitamin B2, and vitamin E have all been suggested as treatment for LHON, but there is currently insufficient evidence to support their use [1,3,6] [1,3,6] [1,3,6].

Coenzyme Q10 is an electron shuttle between complex I and II of the transport chain in the mitochondrial membrane. Coenzyme Q10 deficiency leads to mitochondrial encephalomyopathy because of interruption of oxidative phosphorylation. Treatment with coenzyme Q10 is beneficial in this particular disease. It has been used in other mitochondrial diseases, including LHON, without clear benefit [1,3,6] [1,3,6] [1,3,6].

Back to Top | Article Outline

Idebenone

Idebenone is a short-chain benzoquinone related to coenzyme-Q10 which is capable of preventing reactive oxidative species from causing oxidative damage to cell membranes and mitochondria, and also prevents lipid peroxidation. Idebenone may facilitate bypassing complex I and electron transport directly to complex III [7,8] [7,8].

An in-vitro study of retinal ganglion cells deficient in complex I demonstrated a protective effect of idebenone against cell death [9]. Idebenone was also found to lead to prevention of retinal ganglion cell death, and recovery of vision, in mice treated with rotenone (a complex I inhibitor) as a model of LHON [9].

Following several isolated case reports of idebenone leading to recovery of vision in patients with LHON, Mashima et al. [10] evaluated treatment of LHON patients with idebenone combined with vitamin C and vitamin B2, and found no differences in visual recovery, but proposed that recovery was more rapid when it occurred. A randomized, placebo-controlled, double-blind study of idebenone for patients with LHON (the Rescue of Hereditary Optic Disease Outpatient Study, RHODOS) evaluated patients who received 900 mg/day of idebenone [11]. Although the trial failed to meet the primary outcome, subgroup analysis suggested that patients who had discordant visual acuities at the beginning of the trial (and therefore likely in the early stages of LHON) had better final visual acuities than patients who had more similar visual acuities in the two eyes at enrolment [11].

Dyschromatopsia is a common feature of LHON. Rudolph et al. [12] evaluated the effects on idebenone on color vision in the RHODOS cohort, and found that patients treated with idebenone experienced an improvement in tritan color vision throughout the study, and lost less protan color vision at week 12, but this was not statistically significant at week 24.

Long-term follow-up evaluation of patients enrolled in the RHODOS study was also performed in a single follow-up visit for observational purposes [13]. The results revealed that the effects noted at the end of the RHODOS study persisted beyond the RHODOS trial time parameters, and it was reiterated that early treatment to preserve retinal ganglion cells may lead to the greatest benefit to the patient [13].

Carelli et al. retrospectively evaluated the visual outcomes of 44 patients with LHON who had been treated with idebenone within 1 year of developing vision loss in comparison to those who had not. They found that patients who harbored the 11778/ND4 mutation had a higher rate of visual recovery following treatment with idebenone [14]. These patients with the 11778/ND4 mutation were more likely to experience vision recovery when treated with idebenone earlier in their disease course following initial vision loss. Patients with the 14484/ND6 mutation had a higher rate of spontaneous recovery regardless of treatment, as expected. Although the study was retrospective and nonrandomized, with varying dosages of idebenone used, the authors concluded that idebenone may be an effective treatment for LHON [14]. However, there was no prevention of second eye involvement in the six patients who were treated after involvement of the first eye, and final vision in the second eye was no different than that of the first eye [5].

Back to Top | Article Outline

EPI-743

EPI-743 is a para-benzoquinone, which replenishes glutathione stores and purportedly has much higher antioxidant activity in comparison to idebenone [15,16] [15,16]. The drug was given to five patients with LHON with recent vision loss. Meaningful improvement was objectively achieved by only two patients: one patient who harbored the 11 778 mutation, and one who was a child with the 14 484 mutation who was already predisposed to recovery [17]. One case report described two siblings with LHON because of the 14484/ND6 mutation, one of whom received EPI-743, and one who did not. This report acknowledged that these siblings were predisposed to recovery of vision because they harbored the 14 484 mutation, however the younger sibling who received EPI-743 demonstrated rapid recovery of vision after administration of the drug, whereas the older sibling who did not receive the drug did not recover within the timeframe of follow-up [18]. EPI-743 and idebenone are also being studied for their usefulness in mitochondrial diseases other than LHON. An open label study of EPI-743 used for Leigh's disease demonstrated neurologic improvement in all patients given the drug, and a randomized placebo-controlled trial was recommended to further evaluate the efficacy of this drug [19].

Back to Top | Article Outline

Stem cell therapy

The availability of unproven therapies in areas of the world with less regulation and oversight of medical therapy, combined with the relative ease of international travel, have made the possibility of receiving stem cell infusions for any disease a reality. One case report described a patient with LHON who (purportedly) received umbilical stem cell infusions, both intrathecally and intravenously, with no improvement in vision, and no prevention of the development of optic atrophy [20]. There is currently no evidence that therapy with stem cells improves outcomes in LHON.

Back to Top | Article Outline

Gene therapy

Currently, the most exciting potential means of treating LHON are within the field of gene therapy. LHON's unique characteristics as a mitochondrial disease that primarily affects the eye, with sequential involvement of the second eye, provides a ‘window of opportunity’ for treatment and makes the disorder particularly suitable as an in-vivo ‘laboratory’. There are several forms of gene therapy, which are being evaluated as possible treatments for LHON, at various stages of testing.

Exogenous DNA may be inserted into the nuclear DNA of a cell through viral vectors, such as recombinant adenovirus-associated virus (AAV) type 2. These vectors can be directly inserted into the eye, as has been successfully performed in clinical trials of Leber's congenital amaurosis because of mutations in the nuclear gene RPE65 [21]. As opposed to the nuclear genetic alteration in Leber's congenital amaurosis, the underlying problem in LHON lies in the mitochondrial genome. To circumvent the difficulties of inserting DNA into the mitochondrial genome, allotopic rescue has been employed. In this therapy, new genetic material is incorporated into the nuclear DNA, allowing for protein expression. Proteins encoded by this inserted genetic material can be targeted to translocate to the mitochondria (Fig. 1). This technique was successfully employed in cybrid cell lines, replacing the ND4 protein that was affected by the LHON 11 778 mutation [22,23] [22,23]. Rescue of a mutant mouse model of LHON by this AAV vector containing wild-type allotopic ND4 was successful, with preserved vision, restoration of ATP synthesis, and prevention of loss of retinal ganglion cells and optic nerve axons [24]. Similarly, in a rat model of LHON, Cwerman-Thibault et al. [25▪] demonstrated the safety and efficacy of allotopic expression of wild-type human ND4 introduced by a recombinant AAV2/2 vector containing ND4, providing further evidence that gene therapy through allotopic expression in humans may be possible for LHON. Evaluation of the safety of injecting the viral vector in primates has demonstrated no serious adverse reactions [24].

FIGURE 1

FIGURE 1

As a result of the development of these novel gene therapy techniques, two human LHON gene therapy trials are currently enrolling patients, mostly to initially obtain human safety data [26]. A natural history observational study was performed evaluating patients with the 11 778 mutation to determine the course of visual signs and symptoms, and structural outcomes [27▪]. Data from this study led the authors to decide that the primary outcome for a gene therapy trial should be visual acuity, with a 15-letter ETDRS improvement. Secondary outcomes could include retinal nerve fiber layer thickness, visual fields, and pattern electroretinograms.

As an alternative to using ND4 in viral vectors, NDI1, a yeast nuclear gene which encodes a complex I equivalent, has been used in murine and rat models demonstrating efficacy in protection from a rotenone induced model of LHON [28,29] [28,29]. The proposed advantage of using this gene over ND4 is that this yeast gene would treat all mutations associated with complex I disease by replacing the entire complex I, not just the affected ND4 subunit when replacing the ND4 with the 11 778 mutation with wild-type ND4.

Direct delivery and incorporation of genetic material within the mitochondria proves more difficult than allotopic expression, in part because of the double membrane of the mitochondria and separate system for gene expression. However, successful incorporation of human wild-type mtDNA into mitochondria of cybrid LHON and Leigh syndrome cells was performed by complexing it with recombinant mitochondrial transcription factor A protein [30] (Fig. 2). Mitochondrial respiration and gene expression were found to be increased in these cells [30]. In 2012, Yu et al. [31] described successful delivery and expression of wild-type ND4 in mitochondria of a cybrid cell line that had been targeted for the mitochondria by fusing a targeting sequence to the AAV capsid. This was successfully performed in a murine model of LHON as well and demonstrated efficacy in preventing optic atrophy and vision loss in these mice [31]. Next-generation sequencing found no adverse recombination of the human ND4 within the mitochondrial genome of the transfected mitochondria, indicating that this particular therapy is likely to be well-tolerated in patients with LHON [32]. This vector was evaluated for toxicity and shows promise as another method to be used for a future gene therapy trial [33▪].

FIGURE 2

FIGURE 2

In gene shifting, mutant mtDNA is selectively destroyed, leaving only the nonmutant mtDNA in heteroplasmic mitochondrial diseases (Fig. 3). As described in Reddy et al. [34▪] targeted endonucleases against particular mitochondrial disease haplotypes, including LHON and dystonia, led to elimination of the mitochondrial haplotype in oocytes and embryos, leaving only mitochondria with the selected haplotype, and resulted in phenotypically normal animals. Offspring of the grown adults of oocytes that underwent mitochondrial selection were viable and demonstrated persistence of mitochondrial haplotype selection [34▪]. However, because most patients with LHON are homoplasmic [1–3] [1–3] [1–3], gene-shifting maneuvers would likely not be beneficial for the majority of patients with LHON.

FIGURE 3

FIGURE 3

Nuclear transfer, spindle-chromosomal complex transfer, or spindle transfer are forms of gene therapy treatment for women who wish to have offspring without mitochondrial diseases. One technique removes the pronucleus of a fertilized zygote and places it into a donor zygote that has also had its nucleus removed [35]. Another technique removes the isolated metaphase II spindle of the maternal oocyte and places it into a donor oocyte that has had its nucleus removed [36]. The result is a zygote with normal maternal and paternal nuclear DNA contributions, but with donor cytoplasmic contents, including the mitochondria (Fig. 4). These techniques have been demonstrated to be feasible in primates and human oocytes, although some of the human oocytes displayed abnormal fertilization [36,37] [36,37].

FIGURE 4

FIGURE 4

Back to Top | Article Outline

Genetic counseling and support

In all inherited diseases, genetic counseling, although not a treatment itself, is an essential component of the disease discussion with the patient to inform them of the risk of disease development in their children and relatives. Nearly all patients with LHON are homoplasmic, with all mitochondria expressing the pathogenic mitochondrial DNA. In mitochondrial disorders, men who are carriers of a mutation can be reassured that their offspring will not harbor the mutation. Children of a woman with LHON will all carry the mutation. However LHON has incomplete penetrance. Men who carry a pathogenic mutation have up to a 50% risk of developing LHON, whereas women have about a 10% risk [3].

Patients with LHON have significantly decreased vision-related quality of life [38]. A referral to a low-vision specialist may improve patients’ quality of life through the prescription of low-vision aids and facilitating techniques for reading and mobility [39]. Avoidance of tobacco use and heavy alcohol use should be encouraged in patients and their at-risk maternal relatives [40,41] [40,41].

Back to Top | Article Outline

CONCLUSION

LHON is an inherited mitochondrial disease with devastating visual consequences for those affected. Current treatment options are limited to supportive measures and therapies with questionable benefits. Idebenone can be considered for the patient early in the course of the disease. However, there are many potential therapeutic options that are currently being studied, which may prove to be beneficial in the treatment or prevention of LHON.

Back to Top | Article Outline

Acknowledgements

None.

Back to Top | Article Outline

Financial support and sponsorship

This work was supported in part by an unrestricted departmental grant (Department of Ophthalmology) from Research to Prevent Blindness, Inc., New York, and by Core Grant P30-EY06360 (Department of Ophthalmology) from the National Institutes of Health, Bethesda, MD. N.J.N. is a recipient of the Research to Prevent Blindness Lew R. Wasserman Merit Award.

Back to Top | Article Outline

Conflicts of interest

N.J.N. has acted as a consultant for Santhera Pharmaceuticals and Gensight Biologics. J.H.P. has no conflicts of interest.

Back to Top | Article Outline

Disclosure

Idebenone, EPI-743, and gene therapy are currently not FDA approved for the treatment of Leber hereditary optic neuropathy.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline

REFERENCES

1. Fraser JA, Biousse V, Newman NJ. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol 2010; 55:299–334.
2. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies – disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2011; 30:81–114.
3. Yu-Wai-Man P, Vortuba M, Moore AT, Chinnery PF. Treatment strategies for inherited optic neuropathies: past, present and future. Eye 2014; 28:521–537.
4. Barboni P, Savini G, Valentino ML, et al. Leber's hereditary optic neuropathy with childhood onset. Invest Ophthalmol Vis Sci 2006; 47:5303–5309.
5. Newman NJ. Treatment of hereditary optic neuropathies. Nat Rev Neurol 2012; 8:545–556.
6. Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 18:CD004426.
7. Rauchova H, Vrbacky M, Bergamini C, et al. Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone. Biochem Biophys Res Commun 2006; 339:362–366.
8. Haefeli RH, Erb M, Gemperli AC, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011; 6:e17963.
9. Heitz FD, Erb M, Anklin C, et al. Idebenone protects against retinal damage and loss of vision in a mouse mode of Leber's hereditary optic neuropathy. PLoS One 2012; 7:e45182.
10. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol 2000; 20:166–170.
11. Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134:2677–2686.
12. Rudolph G, Dimitriadis K, Büchner B, et al. Effects of idebenone on color vision in patients with Leber hereditary optic neuropathy. J Neuroophthalmol 2013; 33:30–36.
13. Klopstock T, Metz G, Yu-Wai-Man P, et al. Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy. Brain 2013; 136:e230.
14. Carrelli V, La Morgia C, Valentino ML, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011; 134:e188.
15. Shrader WD, Amagata A, Barnes A, et al. α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging. Bioorg Med Chem Lett 2011; 21:3693–3698.
16. Enns GM, Kinsman SL, Perlman SL, et al. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012; 105:91–102.
17. Sadun AA, Chicani CF, Ross-Cisneros FN, et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol 2012; 69:331–338.
18. Chicani CF, Chu ER, Miller G, et al. Comparing EPI-743 treatment in siblings with Leber's hereditary optic neuropathy mt14484 mutation. Can J Ophthalmol 2013; 48:e130–e133.
19. Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease – genetically defined Leigh syndrome. Mol Genet Metab 2012; 107:383–388.
20. Abukhalil F, Lam BL, Guy J. Visual Observations of an American patient with Leber hereditary optic neuropathy after purported injections of stem cells in China. Arch Ophthalmol 2012; 130:532–534.
21. Bainbridge JWB, Mehat MS, Sundaram V, et al. Long-term effects of gene therapy on Leber's congenital amaurosis. New Engl J Med 2015; 372:1887–1897.
22. Guy J, Qi X, Pallotti F, et al. Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Ann Neurol 2002; 52:534–542.
23. Bonnet C, Kaltimbacher V, Ellouze S, et al. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or v subunits. Rejuvenation Res 2007; 10:127–144.
24. Koilkonda RD, Yu H, Chou TH, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol 2014; 132:409–420.
25▪. Cwerman-Thibault H, Augustin S, Lechauve C, et al. Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss. Mol Ther Methods Clin Dev 2015; 2:15003.

This study demonstrates successful allotopic expression of mitochondrial DNA to replace abnormal mitochondrial proteins to successfully avoid optic atrophy in a rat model of LHON.

27▪. Lam BL, Feuer WJ, Schiffman JC, et al. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy. JAMA Ophthalmol 2014; 132:428–436.

This is a natural history study of LHON. It also describes ideal guidelines for endpoint evaluations for future gene therapy trials of LHON.

28. Marella M, Seo BB, Thomas BB, et al. Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS One 2010; 8:e11472.
29. Chadderton N, Palfi A, Millington-Ward S, et al. Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur J Hum Genet 2013; 21:62–68.
30. Iyer S, Bergquist K, Young K, et al. Mitochondrial gene therapy improves respiration, biogenesis, and transcription in G11778A Leber's hereditary optic neuropathy and T8993G Leigh's syndrome cells. Hum Gene Ther 2012; 23:647–657.
31. Yu H, Koilkonda RD, Chou TH, et al. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A 2012; 109:E1238–E1247.
32. Yu H, Mehta A, Wang G, et al. Next-generation sequencing of mitochondrially targeted AAV transfer of human ND4 in mice. Mol Vis 2013; 19:1482–1491.
33▪. Koilkonda R, Yu H, Talla V, et al. LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: Biodistribution and toxicology profile. Invest Ophthalmol Vis Sci 2014; 55:7739–7753.

This study uses an LHON vector for allotopic expression of mitochondrial DNA to replace abnormal ND4 protein. This study demonstrates that the vector is well tolerated and can be used for a phase I clinical trial.

34▪. Reddy P, Ocampo A, Suzuki K, et al. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 2015; 161:459–469.

The authors describe techniques for editing the mitochondrial genome to prevent expression of abnormal protein, and to prevent transmission of abnormal genes to progeny. This could lead to significant advances in the treatment for heteroplasmic inherited mitochondrial diseases.

35. Craven L, Tuppen HA, Greggains GD, et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 2010; 465:82–85.
36. Tachibana M, Sparman M, Sritanaudomchai H, et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009; 461:367–372.
37. Tachibana M, Amato P, Sparman M, et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493:627–631.
38. Kirkman MA, Korsten A, Leonhardt M, et al. Quality of life in patients with Leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci 2009; 50:3112–3115.
39. Stelmack JA, Tang XC, Reda DJ, et al. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol 2008; 126:608–617.
40. Newman NJ. Leber hereditary optic neuropathy: bad habits, bad vision? Brain 2009; 132:2306–2308.
41. Kirkman MA, Yu-Wai-Man P, Korsten A, et al. Gene-environment factors in Leber hereditary optic neuropathy. Brain 2009; 132:2317–2326.
Keywords:

allotopic transfer; gene therapy; idebenone; Leber hereditary optic neuropathy; mitochondria; optic neuropathy treatment

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.